Novo Nordisk Investing $73M in Clayton, North Carolina, Facility
10/04/2010
"The investment to expand our Clayton facility is another example of our commitment to improving diabetes treatment options in the U.S. by ensuring patients have access to the latest advances in treatment," said Jerzy Gruhn, president of Novo Nordisk Inc. "Insulin delivery devices give people with diabetes a convenient way to manage their health and engage in a productive lifestyle. As patients in the U.S. continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand."
The facility produces Novo Nordisk products including the Levemir FlexPen. The expansion will add two final assembly lines, two packing lines, along with refurbishing the building.
Cost and productivity factors, including state and local incentives, helped Novo Nordisk choose Clayton. The company has been approved for Job Development Investment Grant funds, as well as a $400,000 One North Carolina Fund grant.
Project Announcements
Shinhwa Auto USA Expands Auburn, Alabama, Operations
03/11/2026
General Atomics Expands Shannon, Mississippi, Production Operations
03/11/2026
Starbucks Plans Davidson County, Tennessee, Corporate Operations
03/08/2026
Canada-Based Dainty Foods Plans Batavia Township, Ohio, Manufacturing Operations
03/08/2026
AeroVironment Expands Albuquerque, New Mexico, Manufacturing Operations
03/08/2026
First Quality Home Care Products Plans Archbold, Ohio, Production Facility
03/08/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
The New Industrial Revolution in Biotech
Q4 2025
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
The Skilled Trades Are Ready for a Digital Future
Q4 2025
-
Amazon’s First Mass Timber Delivery Station Tests the Future of Low-Carbon Logistics
Q4 2025